Titan Pharmaceuticals Signs Agreement Adding Probuphine Implant To The Federal Supply Schedule

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal Supply Schedule ("FSS"), providing U.S. veterans

Benzinga · 01/13/2020 13:14

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal Supply Schedule ("FSS"), providing U.S. veterans and other federal government agencies with access to Titan's novel 6-month maintenance treatment for Opioid Use Disorder ("OUD") in eligible patients. The final FSS contract is effective January 15, 2020 and has a five-year term. The FSS contract will extend access to Probuphine to over nine million VA beneficiaries and others within the federal system.